slides · global inventory
Quote
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 18,554
Current window 7,231-7,260
Pages 619
Rows per page 30
Component
7,231-7,260 of 18,554
312
The slide uses a direct quote from an endocrinologist to cast doubt on the company's clinical data integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
327
The slide uses a bolded summary paragraph at the top, followed by a detailed Q&A transcript with yellow highlighting on key quotes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
328
The slide uses a Q&A transcript format to support the thesis that the competitor product is unnecessary or inferior.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
332
The slide uses a direct quote from an endocrinologist to undermine the primary endpoint of a clinical trial.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
338
The slide uses a Q&A transcript format to highlight potential misclassification of adverse events in a clinical trial.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
344
The slide uses a Q&A format to validate the expert's critique of the product's form factor.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
350
The slide presents a Q&A format highlighting expert skepticism regarding the drug's safety profile and market relevance.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
358
The slide uses a Q&A format to highlight skepticism among medical professionals regarding a drug's marketing presentation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
363
The slide highlights a discrepancy between the company's sales pitch and clinical best practices as perceived by an expert.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
367
The slide highlights a direct contradiction between the company's marketing (Vykat) and expert clinical opinion.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
368
The slide highlights the physician's skepticism and the administrative hurdles faced with the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
369
The slide highlights the endocrinologist's reluctance to prescribe the drug, noting that patient pressure was a primary driver for his involvement.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
379
The slide uses a direct quote from a pediatric endocrinologist to undermine the drug's clinical value.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
384
The slide uses a pull-quote style to highlight the expert's hesitation and lack of full support.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
385
The slide highlights a potential safety concern raised by an expert, specifically regarding pre-diabetic and obese patients.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
386
The slide presents a Q&A format where the expert questions the company's motives and the clinical rationale for their product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
388
The slide uses a combination of summary text and direct interview transcripts to build a case against the drug's adoption.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
390
The slide highlights a negative expert opinion on a drug being repurposed for PWS.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
392
The slide uses direct quotes and Q&A excerpts to build a case against the safety of the drug Vykat in the context of PWS treatment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
393
The slide uses highlighted text to emphasize key concerns about Vykat's safety profile and Miller's private skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
394
The slide uses expert interview transcripts to undermine the value proposition of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
398
The slide uses a Q&A format to expose the contradiction between the drug's intended use and its actual clinical viability.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
401
The slide uses a direct quote to undermine the perceived value of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
402
The slide highlights a potential competitive threat to Vykat from generic diazoxide.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
403
The slide highlights a contradiction between the drug's intended use and its physiological impact on a vulnerable patient population.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
404
The slide uses a summary paragraph followed by a direct quote, highlighting the expert's negative sentiment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
405
The slide uses direct quotes from an expert consultation to highlight the drug's perceived lack of efficacy and the barrier of administrative burden.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
408
The slide uses direct quotes from an endocrinologist to frame potential medical risks as a barrier to adoption.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 2 hits
02
The slide uses a bilingual quote (English and Japanese) to set a thematic tone for the presentation.Lasertec Corporation (6920) · Scorpion Capital
Research note Short seller Beat · The Monster2 hits
05
The quote highlights a conflict between administrative credit holds and urgent clinical needs for heart transplants.TransMedics (TMDX) · Scorpion Capital
Research note Short seller Beat · Testimonials from Industry Experts2 hits